Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Repifermin: Phase II

Preliminary data from a 94-patient Phase II

Read the full 79 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE